Evidence map›Paper›PMID 34567451›Full record

ArticleJournal of community hospital internal medicine perspectives2021

Ketamine infusion as a sedative-analgesic in severe ARDS (KISS).

Ramakanth Pata, Pagali Sandeep, Htun Min Aung, Meet J Patel, Tsering Dolkar, Nway Nway, Kosuru Bhanu, Abolfazl Ahmady, Roudabeh Kiani, Ramaiah Swaroop and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of community hospital internal medicine perspectives, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Ketamine-based Sedation Use in Mechanically Ventilated Critically Ill Patients with COVID-19: A Multicenter Cohort Study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Ramakanth PataDepartment of Pulmonary and Critical Care Medicine, Interfaith Medical Center, Brooklyn, NY, USA.ORCID https://orcid.org/0000-0002-9389-2620
Pagali SandeepDepartment of Medicine, Mayo Clinic, Rochester, USA.
Htun Min AungDepartment of Pulmonary and Critical Care Medicine, Interfaith Medical Center, Brooklyn, NY, USA.
Meet J PatelDepartment of Pulmonary and Critical Care Medicine, Interfaith Medical Center, Brooklyn, NY, USA.
Tsering DolkarDepartment of Pulmonary and Critical Care Medicine, Interfaith Medical Center, Brooklyn, NY, USA.
Nway NwayDepartment of Pulmonary and Critical Care Medicine, Interfaith Medical Center, Brooklyn, NY, USA.
Kosuru BhanuUniversity of Pittsburgh Medical Center, USA.
Abolfazl AhmadyDepartment of Pulmonary and Critical Care Medicine, Interfaith Medical Center, Brooklyn, NY, USA.
Roudabeh KianiDepartment of Pulmonary and Critical Care Medicine, Interfaith Medical Center, Brooklyn, NY, USA.
Ramaiah SwaroopDepartment of Pulmonary and Critical Care Medicine, Interfaith Medical Center, Brooklyn, NY, USA.
Frances SchmidtDepartment of Pulmonary and Critical Care Medicine, Interfaith Medical Center, Brooklyn, NY, USA.
Danilo EnriquezDepartment of Pulmonary and Critical Care Medicine, Interfaith Medical Center, Brooklyn, NY, USA.
Interfaith Medical Center · USMayo Clinic · USUniversity of Pittsburgh Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleKetamine has been used as a sedative analgesic in trauma setting, but data regarding its efficacy and safety is lacking in severe ARDS. This retrospective study aims to determine if Ketamine is safer as a sedative agent in mechanically ventilated patients. During the COVID pandemic, as there was a shortage of sedative agents, Ketamine was used.

objectivesThe primary objective was to compare the safety of ketamine to other sedatives. The secondary objective was to compare the effect of ketamine to other sedatives regarding the need for vasopressor, incidence of delirium, infectious complications, acute kidney injury, hospital length of stay, and length of ventilator days.

methodsA retrospective, observational cohort study was conducted. MEASUREMENTS AND MAIN

resultsOne hundred and twenty-four patients (63 men and 61 women) were included. Thirty-four patients received ketamine, while 90 patients received other traditionally used sedatives such as propofol and midazolam. The patients' median age was 64 years in the ketamine group and 68 years in the non-ketamine group. Seventeen patients in the ketamine group (50%) and 65 patients (72%) in the non-ketamine group had mortality (p < 0.02). The hospital length of stay was 22.85 days (± 16.36) in the ketamine group and 15.62 days (± 14.63) in the non-ketamine group (p < 0.02). There was no statistically significant difference among the outcomes of the need for vasopressor, the incidence of delirium, infectious complications, and acute kidney injury.

conclusionsKetamine as a sedative-analgesic agent in COVID-19 patients with severe acute respiratory distress syndrome demonstrated safety with reduced mortality. The ketamine group had a higher hospital length of stay, but a similar complication profile compared to the non-ketamine group. Further prospective randomized controlled trials are warranted to confirm these findings.

Indexed as

anestheticsControlled substancesCOVID-19hypnotics and sedatives

Identifiers

PMID34567451
PMCPMC8462878
OpenAlexW3199991962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.